Current Report Filing (8-k)
02 July 2019 - 8:27PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): June 29, 2019
MEDICAL
INNOVATION HOLDINGS, INC.
(Exact
name of Registrant as specified in its charter)
Colorado
|
000-27211
|
84-1469319
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
5805
State Bridge Road, Suite G-328, Duluth, GA 30097
(Address
of Principal Executive Offices)
(866)
883-3793
(Registrant's
Telephone Number, Including Area Code)
_______________________________________________
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[_] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[_] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b): None
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging
Growth Company
x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
ITEM
4.01
|
CHANGES
IN REGISTRANT’S CERTIFYING ACCOUNTANT
|
Effective
June 29, 2019, Medical Innovation Holdings, Inc. (the “Company”) engaged Prager Metis CPAs LLC of Hackensack, NJ as
the Independent Registered Public Accountant to Audit the Company’s financial statements for the fiscal year ending April
30, 2018. The decision to change accountants was approved by the Company’s Board of Directors.
The
engagement, effective June 29, 2019, of Prager Metis CPAs LLC as the new Independent Registered Public Accountant for the Company
was necessary due to the resignation effective May 31, 2019 of MJF & Associates, the principal accountant which audited the
Company’s financial statements for the fiscal year ended April 30, 2017, and which also had reviewed the Company’s
previously filed quarterly reports on Form 10-Q for the periods ended July 31, 2017, October 31, 2017 and January 31, 2018. The
audit report by MJF & Associates on the financial statements of the Company for the fiscal year ended April 30, 2017 did not
contain an adverse opinion or a disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting
principles, except that the opinion was qualified for the ability of the Company to continue as a going concern.
During
the Company's fiscal year ended April 30, 2018, and the period from May 1, 2018 through May 31, 2019 (i) there were no disagreements
with MJF & Associates on any matter of accounting principles or practices, financial statement disclosure or auditing scope
or procedures that, if not resolved to MJF & Associates satisfaction, would have caused MJF & Associates to make reference
to the subject matter of the disagreement in connection with its reports and (ii) there were no “reportable events”
as defined in Item 304(a)(1)(v) of Regulation S-K.
A
letter addressed to the Commission stating whether MJF & Associates agrees with the statements made by the Company in response
to Item 304(a) of Regulation S-K and, if not, stating the respects in which it does not agree is attached hereto as Exhibit 16.1.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Medical
Innovation Holdings, Inc.
By:
/s/ Ray
De Motte
____________________
Ray
De Motte
Title:
CFO
Date:
July 2, 2019